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Abstract: Metabotropic glutamate receptors (mGlu receptors) have emerged as new therapeutic targets for psychiatric 
disorders, such as schizophrenia, depression and anxiety with their regulatory roles in glutamatergic transmissions. To 
date, several ligands selective for each mGlu receptor have been synthesized, and pharmacological significances of these 
ligands have been demonstrated in animal models. Among them, mGlu2/3 receptor agonists have been proven to be 
effective for treating schizophrenia and anxiety disorders in clinical studies, which may prove utilities of mGlu receptor 
ligands for the treatment of psychiatric disorders. This article reviews recent advances in development of each mGlu 
receptor ligands and their therapeutic potential. 
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1. INTRODUCTION 
  Glutamate is the major excitatory neurotransmitter in the 
brain. It is involved in a wide range of physiological 
processes in the central nervous system that are associated 
with emotion, cognition and motor functions. Glutamate 
receptors are categorized into 2 major types: ionotropic 
glutamate receptors (iGlu receptors), in which the receptors 
have an ion channel structure; and metabotropic glutamate 
receptors (mGlu receptors), which are coupled to G-proteins 
[1, 2]. iGlu receptors, which facilitate fast synaptic 
transmission, are also classified into N-methyl-D-aspartate 
(NMDA),  -amino-3-hydroxy-5-methyl-isoxazole-4-propio-
nate (AMPA) and kainate receptors [1, 2]. mGlu receptors 
also have several isoforms (mGlu1–mGlu8).  
  mGlu receptors are currently classified into 3 groups 
based on their sequence homology, second messenger 
coupling, and pharmacological characteristics (Table 1)     
[3-5]. Group I mGlu receptors include mGlu1 and mGlu5 
that are coupled to phospholipase C, while both group II 
mGlu receptors (mGlu2 and mGlu3) and group III mGlu 
receptors (mGlu4, mGlu6, mGlu7, and mGlu8) are 
negatively coupled to adenylyl cyclase activity. Among these 
mGlu receptors, numerous ligands (agonists, antagonists, 
positive modulators or negative modulators) have been 
developed for the mGlu2/3 and mGlu5 receptors. Studies 
using these ligands have been established their physiological 
and pharmaco-logical significance as well as their possible 
therapeutic applications.  
  A growing body of evidence shows that manipulations of 
the mGlu2/3 and mGlu5 receptors exhibit significant pharma-  
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cological effects in numerous animal models, including 
models for psychiatric disorders. In addition, mGlu2/3 
receptor agonists have demonstrated efficacy in clinical 
studies in patients with schizophrenia [6] or anxiety 
disorders [7-9]. This review will focus on recent develo-
pments of agonists/antagonists, including allosteric modula-
tors for mGlu receptors and the possible therapeutic 
application of these ligands for the treatment of psychiatric 
disorders, such as schizophrenia and depression. 
2. SCHIZOPHRENIA 
2.1. Role of Glutamatergic Transmission in 
Schizophrenia 
  In addition to the well-established “dopamine hypothesis 
of schizophrenia,” it has also been suggested that 
abnormalities of glutamate transmission are involved in the 
pathophysiology of schizophrenia. Significantly lower levels 
of glutamate are found in the cerebrospinal fluid (CSF) and 
in postmortem brain tissues of schizophrenic patients [10, 
11]. CSF glutamate levels are also inversely correlated with 
the severity of positive symptoms in unmedicated patients 
[12]. Phencyclidine (PCP) and ketamine, non-competitive 
NMDA receptor antagonists, produce transient psychoses, 
disrupted affect and caused cognitive impairments in healthy 
volunteers, all of which are similar to what are observed in 
schizophrenia [13-16], and lead to profound exacerbations of 
pre-existing symptoms in schizophrenic patients [15]. 
Moreover, NMDA receptor antagonists and transgenic 
manipulation of an NMDA receptor subunit (NR1) induce 
schizophrenia-like behavioral abnormalities (increased loco-
motor activity, reduced social interaction, cognitive dysfunc-
tion), which are ameliorated by antipsychotic treatments [17-
19].  
  Thus, glutamatergic dysfunction, and hypofunction of 
NMDA receptors in particular, may have an important role 
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receptors have modulatory roles on NMDA receptor-
mediated transmission, mGlu receptor ligands may be 
attractive therapeutic targets for the treatment of 
schizophrenia. 
2.2. mGlu2/3 Receptor Agonists/mGlu2 Receptor 
Potentiators 
  In recent years, several lines of evidence have shown that 
mGlu2/3 receptor agonists may be effective for the treatment 
of schizophrenia in both animal models and in humans. 
mGlu2/3 receptor agonists, such as (1S,2S,5R,6S)-2-
aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY3547 
40), have been reported to attenuate locomotor hyperactivity 
induced by an NMDA receptor antagonist in rodents [20]. 
Similar effects were observed with other mGlu2/3 receptor 
agonists, including (-)-(1R,4S,5S,6S)-4-amino-2-sulfony-
lbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) 
[21], (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-
dicarboxylic acid (LY379268) [22], (1S,2S,3S,5R,6S)-2-
amino-3-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
(MGS0008), and (1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicy-
clo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0028) [23]. 
Moreover, mGlu2/3 receptor agonists have been shown to 
inhibit amphetamine-induced locomotor hyperactivity  [21, 
24] and conditioned avoidance responding [21, 25]. These 
models may be predictive of the efficacy for positive 
symptoms of schizophrenia. Therefore, mGlu2/3 receptor 
agonists may be effective for the treatment of positive 
symptoms of schizophrenia.  
  The effect of LY404039 on PCP- or amphetamine-
induced locomotor hyperactivity is absent in mGlu2 
receptor- or mGlu2/3 receptor-null mice, but not in mGlu3 
receptor-null mice [26]. In addition, the effects of mGlu2/3 
receptor agonists on PCP- or amphetamine-induced 
locomotor hyperactivity were mimicked by the selective 
mGlu2 receptor potentiator N-(4-(2-methoxyphenoxy)phe-
nyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine 
(LY487379) [24]. Thus, the mGlu2 receptor, but not the 
mGlu3 receptor, is responsible for the antipsychotic actions 
of mGlu2/3 receptor agonists. 
  LY354740 improved PCP-impaired performance in a T-
maze discrete-trial delayed alternation task [20] and reversed 
the deficits of social discrimination induced by neonatal 
treatment with PCP [27]. These findings suggested the 
potential of mGlu2/3 receptor agonists to improve the 
cognitive dysfunctions observed in schizophrenic patients. 
However, there are some contradictory findings indicating 
that mGlu2/3 receptor agonists may not improve cognitive 
dysfunction, and may even cause it to deteriorate.  
  For example, LY354740 induced working memory 
deficits in delayed matching and non-matching to position 
and spatial memory tasks in a Morris water maze [28], and 
did not improve PCP-induced cognitive deficits in a 
spontaneous alternation task and passive avoidance task [29]. 
Moreover, mGlu2/3 receptor agonists did not reverse 
amphetamine- or PCP-induced disruption of prepulse 
inhibition (PPI) [24, 30], a fundamental form of information 
processing that is impaired in schizophrenic patients.  
  In contrast, a selective mGlu2 receptor potentiator, 
LY487379, significantly improved amphetamine-disrupted 
PPI [24], and also significantly improved social 
discrimination deficits induced after neonatal treatment with 
PCP [28]. Based on these findings, the effects of mGlu2/3 
receptor agonists may be task-dependent or influenced by the 
conditions that were used. It is also conceivable that 
selective mGlu2 receptor stimulation may be important in 
order to fully exert its effects on cognitive dysfunction, while 
mGlu3 receptor stimulation may have opposite effects. 
  The neuronal mechanisms by which mGlu2/3 receptor 
agonists exert their effects have been investigated. mGlu2/3 
receptor agonists are considered to exert their effects by 
acting on the glutamatergic, dopaminergic, and 5-HTergic 
pathways. Administration of NMDA receptor antagonists 
increases glutamate release in the prefrontal cortex, and also 
elicits working memory dysfunction [20, 31, 32]. Thus, it is 
presumed that NMDA receptor dysfunction in the prefrontal 
cortex increases glutamate release and, thereby, impairs 
working memory.  
  mGlu2/3 receptor agonists have been shown to attenuate 
the increased glutamate release caused by blockade of 
NMDA receptors. Consistent with this result, a marked 
increase in relative cerebral blood volume, which reflects 
hypermetabolism associated with increased glutamate 
release, was seen in the prefrontal cortex in rats following 
Table 1.  Classification and Characteristics of mGlu Receptors 
 
   Group I   Group II   Group III 
   mGlu1  mGlu5  mGlu2  mGlu3  mGlu4  mGlu6  mGlu7  mGlu8  
Structure  Class C GPCR  Class  C  GPCR  Class  C  GPCR  
Signaling   Gq/11 
Activation of phospholipase C 
Gi/o   
Inhibition of adenylyl cyclase 
Gi/o 
Inhibition of adenylyl cyclase 
Agonists  DHPG CHPG 
LY404039, 
LY354740, 
MGS0028, 
MGS0008 
LY404039, 
LY354740, 
MGS0028, 
MGS0008 
L-AP4, 
PHCCC  HomoAMPA  L-AP4, 
AMN082 
L-AP4, 
RS-PPG 
Positive 
allosteric  
modulators 
  
DFB, CDPPB,  
CPPHA,  
ADX47273 
LY487379, 
BINA 
         AMN082    
Antagonists   JNJ16567083, 
LY367385 
MPEP, MTEP  LY341495, 
MGS0039 
LY341495, 
MGS0039 
CPPG CPPG CPPG  CPPG 22    The Open Medicinal Chemistry Journal, 2010, Volume 4  Yasuhara and Chaki 
administration of PCP, as determined by pharmacological 
magnetic resonance imaging. LY354740 attenuated this 
metabolic hyperactivity [33]. Given that prefrontal abnor-
mallities are assumed to be involved in the etiology of 
schizophrenic symptoms, attenuation of prefrontal abnormal-
llities (glutamate overflow and hypermetabolism) may con-
tribute to the antipsychotic actions of mGlu2/3 receptor 
agonists. 
  Moreover, an mGlu2/3 receptor agonist inhibited PCP-
increased dopamine flow in the nucleus accumbens shell 
[34], while it increased dopamine release in the prefrontal 
cortex [21, 35]. Given that accumbal dopaminergic hyperac-
tivity is associated with positive symptoms of schizophrenia, 
while prefrontal dopaminergic hypoactivity is associated 
with impairment of cognition, these differential effects of 
mGlu2/3 receptor agonists could contribute to the antipsyc-
hotic effects of mGlu2/3 receptor agonists. 
  Recently, interactions between the 5-HT2A and mGlu2 
receptors have been suggested. LY354740 attenuated 
serotonin-induced excitatory postsynaptic currents recorded 
in layer V pyramidal cells of the medial prefrontal cortex, 
suggesting that mGlu2/3 receptors negatively regulated 5-
HT2A receptor-mediated responses to stimulate glutamate 
release, presumably from thalamocortical afferents to the 
prefrontal cortex. Moreover, LY354740 attenuated 5-HT2A 
receptor agonist-induced head shakes in rats [36]. 
Attenuation of 5-HT2A receptor-mediated electrophysio-
logical and behavioral responses was mimicked by an mGlu2 
receptor potentiator [37], indicating that the mGlu2 receptor, 
but not the mGlu3 receptor, was involved in this event. It 
was also recently shown that the 5-HT2A and mGlu2 
receptors formed a heterodimeric complex [38]. Thus, it is 
intriguing to assume that the mGlu2 receptor may exert its 
effects, in part, by inhibiting 5-HT2A receptor signaling via 
the mGlu2 receptor-5-HT2A receptor complex. 
  The efficacy of an mGlu2/3 receptor agonist, LY2140023 
(a methionine amide of LY404039), was reported in a 
randomized, double-blinded, placebo-controlled study of 196 
schizophrenic patients [6]. LY2140023 significantly 
improved both positive and negative symptoms, as observed 
with olanzapine. LY2140023 neither increased prolactine nor 
worsened extrapyramidal symptoms. Furthermore, LY2140 
023 did not affect body weight unlike olanzapine, which 
causes increased body weight. Therefore, mGlu2/3 receptor 
agonists may be effective and safe as monotherapy for the 
treatment of schizophrenia, although larger and longer-term 
studies are needed to verify this. 
2.3. mGlu5 Receptor Agonists/mGlu5 Receptor 
Potentiators 
 ( RS)-2-Chloro-5-hydroxyphenylglycine (CHPG), an 
mGlu5 receptor agonist, has been reported to attenuate 
ketamine-induced increases in locomotor hyperactivity, and 
to improve PPI disruption and object recognition memory 
impairment induced by ketamine [39]. Similarly, CHPG 
ameliorated PPI disruption induced by amphetamine [40], 
indicating that mGlu5 receptor stimulation exerts 
antipsychotic activity in animal models. mGlu5 receptor 
potentiators offer an attractive alternative to the direct 
mGlu5 receptor activation by orthosteric competitive 
agonists. 
  To date, several structurally diverse mGlu5 receptor 
potentiators have been reported, including 3,3’-difluoro-
benaldazine (DFB), S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phe-
nyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone 
(ADX47273) and 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide (CDPPB). These compounds reportedly pre-
vented locomotor hyperactivity induced by PCP, ketamine, 
amphetamine, and apomorphine [39, 41, 42]. ADX47273 
also reduced conditioned avoidance responding in rats [42]. 
These findings suggest that mGlu5 receptor potentiation may 
be effective for the positive symptoms of schizophrenia. 
  The efficacy of mGlu5 receptor potentiators for cognitive 
dysfunctions has also been reported. CDPPB improved PPI 
disruption induced by amphetamine [41]. In a novel object 
recognition test, CDPPB or DFB improved the impaired 
recognition capability that was induced by MK-801 or 
ketamine [42, 43]. CDPPB also attenuated MK-801-impaired 
task performance in a set-shifting paradigm [44]. Therefore, 
enhancement of mGlu5 receptor activity with mGlu5 
receptor potentiators may be effective for treating the 
dysfunctions of several cognitive domains associated with 
schizophrenia. 
  In addition to improving cognitive deficits, mGlu5 
receptor potentiators, including ADX47273, DFB, and 
CDPPB, also enhanced object recognition memory in a 
novel object recognition test [42] and spatial memory in Y-
maze spatial alternation [45] and Morris water maze tasks 
[46], indicating that mGlu5 receptor potentiators may have 
memory-enhancing effects, even for normal conditions. The 
involvement of the mGlu5 receptor on cognition is supported 
by a study of mGlu5 receptor-null mice. These mice 
exhibited reduced long-term potentiation in the CA1 region 
and dentate gyrus of the hippocampus (NMDA receptor-
dependent pathways), but not in the CA3 region (an NMDA 
receptor-independent pathway). mGlu5 receptor-null mice 
also displayed impaired spatial learning in a Morris water 
maze task, impaired contextual learning during fear-condi-
tioning [47] and disrupted PPI [40]. 
  The neuronal mechanisms by which mGlu5 receptor 
potentiation exerts antipsychotic and cognitive enhancing 
effects have been considered in relation to stimulation of 
NMDA receptor function. The mGlu5 receptor positively 
regulates NMDA receptor function. mGlu5 receptor agonists 
potentiated NMDA receptor function in multiple neuron 
populations [48, 49], and this was not observed in knockout 
mice lacking mGlu5 receptors. Similarly, an mGlu5 receptor 
potentiator,  N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoi-
ndol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA), 
potentiated NMDA currents in hippocampal slices induced 
by a threshold level of DHPG [50]. In addition, an mGlu5 
receptor potentiator, CDPPB, prevented MK-801-induced 
excessive firing and reduced spontaneous bursting in the 
medial prefrontal cortex [51]. These findings indicate that 
mGlu5 receptor stimulation may ameliorate abnormalities in 
prefrontal cortical neuronal activity, which may be responsi-
ble for frontal cortex dependent cognitive function.  
  Conversely, mGlu5 receptor antagonists potentiated the 
spontaneous burst and spike activity of cortical neurons [52] 
and psychotomimetic effects, both of which were induced by 
NMDA receptor antagonists [49]. Interactions between the 
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been indicated by reports showing that an mGlu5 receptor 
agonist, DHPG, increased phosphorylation of NMDA NR1 
at Ser-897 (a substrate for protein kinase C) in brain slices 
[53], and that administration of DHPG also increased 
phosphorylation of NR1 at Ser-897 [54]. Because decreased 
Ser-897 on the NR1 receptor has been reported in the brains 
of schizophrenic patients, and antipsychotic drugs increased 
Ser-897 on NR1 [55, 56], an increase of Ser-897 
phosphorylation on NR1 by mGlu5 receptor stimulation is of 
interest in light of the mGlu5 receptor involvement in 
schizophrenia. 
2. 4. mGlu1 Receptor Antagonists 
  mGlu1 receptor antagonists such as [4-[1-(2-fluoropyri-
dine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-me-
thyl-3,6-dihydropyridine-1(2H)-carboxamide] (FTIDC) and 
2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-
1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one (CFMTI) 
have been reported to exhibit antipsychotic effects in rodent 
models of schizophrenia. Of note, these mGlu1 receptor 
antagonists reduced maximal responses of L-glutamate [57, 
58], suggesting that both compounds acted as non-
competitive antagonists for the mGlu1 receptor. Thus, 
FITDC antagonized methamphetamine-induced locomotor 
hyperactivity and methamphetamine-disrupted PPI [59].  
 Antipsychotic-like potentials of mGlu1 receptor 
antagonists have been further characterized by studies using 
a potent and selective mGlu1 receptor antagonist CFMTI 
[58]. As observed with FTIDC, at the doses which 
antagonizes mGlu1 receptor-mediated behavior (face-
washing behavior), CFMTI reduced methamphetamine-
induced locomotor hyperactivity and disruption of PPI 
without affecting spontaneous locomotor activity. Moreover, 
CFMTI attenuated locomotor hyperactivity and PPI 
disruption induced by ketamine, and reversed MK-801-
reduced social interaction (regarded as social withdrawal, 
one of the negative symptoms). Therefore, based on animal 
studies, mGlu1 receptor antagonists may have efficacy for 
positive and negative symptoms, and a certain domain of 
cognitive dysfunction of schizophrenia.  
  In contrast, mGlu1 receptor antagonists neither induced 
catalepsy nor impaired rotarod performance [58, 59], 
suggesting that mGlu1 receptor antagonists may not cause 
motor dysfunction, unlike the actions of typical 
antipsychotics. This atypical activity of mGlu1 receptor anta- 
gonists is further supported by c-fos induction, in that CFTI 
induces c-fos in the medial prefrontal cortex and nucleus 
accumbens, but not in the dorsolateral striatum, which is in 
line with the results using clozapine [58]. 
 The neurochemical mechanisms underlying the 
antipsychotic actions of mGlu1 receptor antagonists are not 
fully understood. Injection of DHPG, a group I mGlu 
receptor agonist, into the medial prefrontal cortex increased 
glutamate release, and an mGlu1 receptor antagonist blocked 
this [60]. Thus, regulation of glutamate overflow in the 
medial prefrontal cortex by mGlu1 receptor blockade may be 
responsible for the pharmacological actions of mGlu1 
receptor antagonists. 
3. MOOD DISORDERS 
3. 1. Role of Glutamatergic Transmission in Depression 
  Emerging evidence suggests that abnormalities of 
glutamatergic systems are involved in depression, although 
the extent and direction of these changes remain subjects of 
debate. Blood glutamate levels have been shown to increase 
in medicated patients [61, 62]. Mitani et al. [63] reported 
that increased glutamate plasma levels reflected the severity 
of depression. Sanacora et al. [64] reported significantly 
increased glutamate levels in the occipital cortex in 
depressed patients as compared to healthy controls.  
  In contrast, glutamate levels in the anterior cingulate 
cortex and frontal cortex of patients with major depression 
were reduced [65, 66], while total REM sleep suppression, 
an efficient method for relieving depression, produced robust 
increases in glutamate levels in the pons [67]. Pfleiderer et 
al. [68] reported reduced Glx (glutamate/glutamine) levels in 
the left anterior cingulate cortex in severely depressed 
unipolar patients, which were normalized by electrocon-
vulsive therapy. Abnormalities in expression levels of the 
NMDA receptor and glial type glutamate transporters 
(EAAT1 and EAAT2) have been reported in postmortem 
studies of human suicide victims and major depression [69, 
70].  
  In addition, ketamine (an NMDA receptor antagonist) 
and riluzole (a glutamate modulator) exerted antidepressant 
activities in patients with major depressive disorders who 
were unresponsive to conventional antidepressants [71 – 73]. 
In particular, ketamine reportedly exerted a rapid, sustained 
and robust antidepressant effect. Thus, modulation of 
glutamatergic transmission might be an effective approach to 
treating patients with depression, in particular patients with 
treatment-resistant depression. 
3. 2. mGlu2/3 Receptor Antagonists 
  Recently, the mGlu2/3 receptor was shown to be 
involved in depression using selective mGlu2/3 receptor 
antagonists in rodent models. mGlu2/3 receptor antagonists, 
MGS0039 and LY341495, shortened immobility times in 2 
behavioral despair models, a rat forced swim test, and a 
mouse tail suspension test [74]. Similar antidepressant 
effects of an mGlu2/3 receptor antagonist in a despair model 
were confirmed by Witkin et al. [75]. An antidepressant-like 
phenotype (reduced immobility time) in a forced swim test 
was observed in knockout mice lacking mGlu2 receptors 
[76], suggesting that the mGlu2 receptor may be involved in 
the antidepressant effects of mGlu2/3 receptor antagonists. 
In addition, LY341495 attenuated the threshold elevations 
observed in rats undergoing spontaneous nicotine withdrawal 
[77]. The threshold elevation following withdrawal from 
chronic treatment with drugs of abuse has been proposed to 
reflect anhedonia (loss of interest or pleasure), which is a 
core symptom of depression [78], and provides additional 
evidence that mGlu2/3 receptor antagonists may have 
antidepressant effects. Moreover, subchronic administration 
of MGS0039 reduced escape failures in a learned 
helplessness paradigm, indicating antidepressant activity 
[79].  
  Neuronal mechanisms underlying the antidepressant 
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investigated. For example, MGS0039 increased the firing 
rate of the dorsal raphe nucleus and increased serotonin 
release in the medial prefrontal cortex [80]. This was 
consistent with the behavioral profile in the forced swim test 
that showed that mGlu2/3 receptor antagonists selectively 
increased swimming behavior, as did SSRIs. In addition to 
serotonergic transmission, MGS0039 increased dopamine 
release in the nucleus accumbens shell [81], which may 
explain the anti-anhedonic effect of mGlu2/3 receptor 
antagonists, as dopaminergic activity in the nucleus 
accumbens is closely related to reward activity. Also, 
subchronic administration of MGS0039 increased 
hippocampal neurogenesis [82], which has been shown to be 
one mechanism for the actions of antidepressants.  
  Interestingly, some of the actions of MGS0039 were 
attenuated by an AMPA receptor antagonist, NBQX [83, 
84], suggesting that MGS0039 exerts its effects through 
AMPA receptor activation. Given that AMPA receptor 
potentiators have been shown to exhibit antidepressant 
effects in animal models [85], and that AMPA receptor 
activation has been suggested to be involved in the 
antidepressant actions of ketamine and riluzole [86, 87], 
which are effective antidepressant treatments, this 
mechanism is of interest in terms of the efficacy of mGlu2/3 
receptor antagonists for the treating depression in the clinic. 
3. 3. mGlu5 Receptor Antagonists 
  The antidepressant potentials of mGlu5 receptor 
antagonists have been investigated using selective allosteric 
negative modulators, such as 6-methyl-2-(phenylethynyl)-
pyridine (MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-
pyridine (MTEP). Both compounds reduced immobility 
times in despair models, such as forced swim and tail 
suspension tests [88-90]. The antidepressant effects of MPEP 
in the forced swim test were no longer observed in knockout 
mice lacking mGlu5 receptors [88], indicating that these 
compounds exerted their effects via the mGlu5 receptor. 
Moreover, subchronic administration of MPEP or MTEP 
attenuated abnormal behaviors (learning deficits in a passive 
avoidance paradigm or locomotor hyperactivity in a novel 
environment) induced by olfactory bulbectomy [89, 91]. 
Molina-Hernandez et al. [92] reported that MTEP injection 
into the lateral septal nuclei increased reinforced lever 
presses and caused a comprehensive rightward shift of the 
inter-response time, as observed with desipramine in the 
differential-reinforcement-of-low-rate 72-s paradigm, thus 
providing additional evidence for mGlu5 receptor 
antagonists for antidepressant treatment. 
  The neuronal mechanisms underlying the antidepressant 
effects of mGlu5 receptor antagonists have not been fully 
elucidated. Interactions between the mGlu5 and NMDA 
receptors have been proposed to be involved in the actions of 
mGlu5 receptor antagonists. As described in [2.3], the 
mGlu5 receptor positively regulated NMDA receptor 
function. Thus, mGlu5 receptor blockade may have a 
negative impact on NMDA receptor function. This is 
interesting, as NMDA receptor antagonists like ketamine 
have been proven to be a very effective approach for treating 
depression in both animal models and clinical studies [71, 
72, 87]. Moreover, mGlu5 receptor activation on astrocytes 
increases glutamate release from glial cells in the nucleus 
accumbens, and glutamate released from glial cells 
selectively activates extrasynaptic NR2B-containing NMDA 
receptors, but not intrasynaptic NR2A-containing NMDA 
receptors [93]. Because increased glutamate release from 
glial cells, which leads to stimulation of extrasynaptic 
NMDA receptors, has been considered to be among the 
causes of depression, indirect extrasynaptic NMDA receptor 
blockade by mGlu5 receptor antagonists could be a very 
interesting approach to treating depression. 
3. 4. mGlu7 Receptor Ligands 
  Roles for the mGlu7 receptor in depression have been 
studied, although its involvement is rather complicated. 
Knockout mice lacking mGlu7 receptors displayed 
antidepressant-like phenotypes in a forced swim test and a 
tail suspension test without significant changes in locomotor 
activities [94]. mRNA expression levels of the glucocor-
ticoid and 5-HT1A receptors in the hippocampus increased 
in mGlu7 receptor-null mice [95], suggesting that a feedback 
mechanism within the HPA axis may be enhanced. In line 
with this observation, mGlu7 receptor-null mice showed 
hypersensitivity to dexamethasone, as demonstrated by a 
marked serum corticosterone reduction in response to 
dexamethasone challenge [95]. This is opposite to what is 
seen in many depressed patients who have a blunted 
response to dexamethasone challenge [96].  
  In contrast, N,N'-dibenzhydrylethane-1,2-diamine dihy-
drochloride (AMN082), an allosteric mGlu7 receptor 
agonist, exhibited antidepressant effects in forced swim and 
tail suspension tests [97]. The antidepressant effect of 
AMN082 was not observed in knockout mice lacking mGlu7 
receptors, showing that AMN082 exerted its effect through 
mGlu7 receptor activation. Contradictory findings between 
stimulation and blockade of this receptor remain to be 
resolved.  
  Although not statistically significant, results with mGlu7 
receptor-null mice showed increased locomotor activity, 
which may affect the outcomes in the forced swim test. In 
addition, the mGlu7 receptor undergoes rapid internalization 
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upon stimulation with AMN082 [98], which, in turn, may 
lead to mGlu7 receptor blockade. There are several issues to 
be resolved regarding the neuronal mechanisms by which 
mGlu7 receptor affects depressive states, including its sites 
of action and relationships with other glutamate receptors. 
4. CHEMISTRY 
4.1. mGlu2/3 Receptor Agonist/mGluR2 Receptor 
Potentiators 
  In initial studies investigating the functions of mGlu2/3 
receptors, L-CCG-I, ACPD and DCG-IV were used as non-
selective ligands and conformationally restricted glutamate 
analogs (Fig. 1) [99-101]. LY354740 was described in 1997 
as the first potent and selective agonist for mGlu2/3. It 
activates the mGlu2 (EC50 = 5 nM) and mGlu3 (EC50 = 24 nM) 
receptors in vitro and has potent pharmacological effects in 
animals [102]. LY354740 is a comformationally restricted 
bicycloamino acid, (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hex-
ane-2,6-dicarboxylic acid. For this type of bicyloamino acid, 
in the 2-position of the bicyclohexane ring, LY379268 has 
an oxygen atom, LY389795 has a sulfur atom, and 
MGS0028 has an oxo group [23, 103]. These compounds 
have been reported to have highly potent mGlu2/3 receptors 
agonist activities.  
  Two compound series have been reported as mGlu2 
receptor allosteric potentiators (Fig. 2 ). The first series 
includes an allosteric modulator of the mGlu2 receptor from 
an  N-aryl pyrinin-3-ylmethylsulfonamide derivative, 4-
MPPTS [104]. In this compound type, cyPPTS is a very 
potent potentiator (24 nM) [105]. Another series of 
compounds results from 4’-alkoxyacetophenone derivatives, 
and is typified by compound 1. Compound 1 is a selective 
mGlu2 receptor potentiator (300 nM) with no allosteric 
activities against mGlu1, 3, 4, 5, 7 or 8 [106, 107]. 
4.2. mGlu2/3 Receptor Antagonists 
  Compared with other receptor subtypes, mGlu2/3 
receptor antagonists have rarely been reported in the 
literature. In 1996, a glutamate analog, LY341495, was 
disclosed as a selective competitive mGlu 2/3 receptor 
antagonist in a patent application (Fig. 3) [108]. LY341495 
has nanomolar affinities for mGlu 2/3 receptors [109, 110]. 
MGS0039 containing a bicyclo[3.1.0]hexane ring system 
was reported to have nanomolar affinities for mGlu 2/3 
receptors [111]. The series of mGlu 2/3 receptors antagonists 
that have amino acid moieties are found at low levels in the 
CNS. In fact, ester prodrugs of MGS0039 are reported to 
deliver MGS0039 after hydrolytic release of the ester 
prodrugs [112]. 
  New classes of mGlu 2 antagonists without amino acid 
moieties have been identified. Triazole derivative 2 was 
reported as an antagonist with moderate affinity for the 
mGlu 2 receptor (Ki = 0.1 μM) [113]. A series of patents 
were published on benzodiazepine derivative 3, which 
reportedly had a very low nanomolar affinity for the mGlu 2 
receptor [114]. Thiazolopyrimidine derivative 4 and pyrrazo-
lopyrimidine derivative 5 represented novel structural 
templates for mGlu 2 receptor antagonists [115 – 119]. 
Thiazolopyrimidine derivatives showed moderate binding 
affinity for the mGlu 2 receptor, while pyrrazolopyrimidine 
had low nanomolar affinity. Recently, a structurally different 
mGlu 2 receptor antagonist, imidazole 6, was disclosed 
(binding affinity for mGlu 2 receptor (IC50= 7nM) [120]. 
These new classes of mGlu 2 receptor antagonists have 
limited disclosures regarding the details of their subtype 
selectivities, their modes of binding, including activities as 
competitive and non-competitive modulators, binding sites, 
and their pharmacology. 
4.3. mGlu1 Receptor Antagonists 
  Competitive mGlu1 receptor antagonists are poorly 
represented in the literature. Fig. (4) shows some selective 
competitive mGlu1 receptor antagonists. These antagonists 
are analogs of glutamine and phenylglycine. (S)-4-CPG, a 
phenylglycine analog, is a selective antagonist with weak 
effects for the mGlu2 receptor [121]. The 2-Methyl analog of 
(S)-4-CPG, LY367385, is more potent and more selective 
than (S)-4-CPG for the mGlu1 receptor, without any effects 
for the group II mGlu receptors [122]. AIDA, a 
conformationally restricted analog between the phenyl group 
and an amino acid carbon, selectively antagonizes the mGlu1 
receptor, with weak effects for the mGlu5 and 2 receptors 
[123, 124]. Compound 7, with a replacement in the phenyl 
ring of (S)-4-CPG with cuban is a potent, selective 
antagonist for the mGlu1 receptor [125, 126]. Since 
competitive mGlu1 receptor antagonists show poor 
 
 
 
 
 
 
 
 
Fig. (2). mGlu2 receptor potentiators. 
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potencies, selectivities, and levels of CNS exposure, they 
have not yet become clinically useful therapeutic agents 
[127, 128]. 
  Negative allosteric mGlu1 receptor modulators are 
structurally different from glutamate and phenylglycine. 
Several different structures are shown in Fig. (5.) CPCCOEt 
was first identified as a negative allosteric modulator in the 
late 1990s [129-131]. Then, several new classes of mGlu1 
receptor antagonists that were structurally distinct from 
CPCCOEt were identified. BAY36-7620, containing 
butyrolactone, is a potent (IC50 = 160 nM) and selective 
antagonist for the mGlu1 receptor. It inhibits >60% of 
mGlu1a receptor constitutive activity (IC50 = 380 nM). Thus, 
BAY36-7620 was the first mGlu1 receptor inverse agonist to 
be described [132]. At about the same time, some different 
types of heteroaromatic compounds were reported. 
Compound  8 containing an indole ring shows a low 
micromole affinity for the mGlu1 receptor, and pyridine ring 
fused indole derivatives 9 is also a low affinity mGlu1 
receptor antagonist [133, 134]. A series of patents were 
published on YM-29818 containing a thiazolobenzimidazole 
ring [135-137]. The specificity of YM-29818 for the mGlu1 
receptor (IC50 = 16 nM) included subtypes 2 to 7, as well as 
several other receptors, transporters, and ion channel targets. 
From in vivo experiments, orally administered YM-298198 
showed a significant analgesic effect in streptozotocin-
induced hyperalgesic mice (30 mg/kg) [138]. In 2006, in a 
series of tricycloaromatics, novel pyridothienopyrimidine 
derivatives were reported as mGlu1 receptor antagonists, 
such as 10, that had IC50 values of <50 nM [139]. 
   Quinoline and quinoxaline derivatives, such as 11   
and  12, were found to be mGlu1 receptor antagonists. 
Compound 11 exhibited high activity for the mGlu1 receptor 
(IC50 = 2.97 nM) [140]. Compound 12 had good affinity for 
the mGlu1 receptor (IC50 = 52n M) and no affinity for 
mGlu5 receptor (IC50 = 7289 nM) [141]. 
  A series of heteroaromatics and cycloamine derivatives, 
13–19, were also published. Benzoazepine and pyrimidine 
derivative 13 has an IC50 value of 3 nM for binding affinity 
to the mGlu1 receptor, an IC50 value of 9 nM [142]. Pyrazine 
analog 14 also shows high binding affinity for the mGlu1 
receptor (IC50 = 6 nM) [143]. Piperazine derivative 17, 
modified from benzoazepine moiety in 14 to phenyl-
piperazine, is a potent negative allosteric modulator of the 
mGlu1 receptor (IC50 = 23 nM) [144]. In 2006, N-pyridyl- 
and  N-phenyl-piperazine derivatives were identified. Com-
pounds  16 and 17 had reported affinities for the mGlu1 
receptor of 6.9 nM and 38 nM, respectively, and antagonized 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Antagonists of mGlu 2 receptor. 
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the increase of locomotor activity in rats with amphetamine 
at a dose of 30 mg/kg [145, 146]. 
 Recently, novel diaryl substituted 5-membered 
heteroaromatic derivatives 18 and 19 were disclosed. 
Compound 18 exhibited an IC50 value of 2.3 nM and activity 
against the disruption of prepulse inhibition in 
methamphetamine treated rats at 1–10 mg/kg [147, 148]. 
4.4. mGlu5 Receptor Agonists/mGlu5 Receptor 
Potentiators 
  3,5-DHPG was identified as the first group I receptor 
selective agonist (Fig. 6). However, 3,5-DHPG lacks subtype 
selectivity and has low potency [149, 150]. In 1999, 
compounds 20 and 21 were described as selective mGlur5 
receptor agonists. Their EC50 values were 11 nM and 49 nM, 
respectively [151]. Their apparent higher potency and 
selectivity for mGlu5 receptor might make these compounds 
important new pharmacological tools. Despite these 
significant advances, highly potent and subtype-selective 
competitive mGlu receptor agonists have not been identified. 
  In an attempt to overcome the low potency, low 
selectivity, and poor blood-brain barrier permeation of most 
mGlu receptor ligands, investigations of non-competitive 
mGlu5 receptor modulators began in the mid-1990s. mGlu5 
receptor positive allosteric modulators began to be 
developed after 2000. Three different structural types of 
mGlu5 receptor positive allosteric modulators were reported: 
DFB, CDPPB, and CPPHA [152-154]. These modu-lators do 
not affect ligand binding to the orthosteric glutamate binding 
site, but potentiate its response to glutamate. DFB and 
CDPPB bind to the MPEP site and displace binding of 
radioligand to a well-characterized binding site for MPEP 
[155, 156]. Thus, some reports indicate that these 
compounds have antipsychotic-like effects [156, 157].  
  In 2005, a fourth structural series, ADX-47273, was 
reported by Addex pharm with similar properties [158, 159]. 
4.5. mGlu5 Receptor Antagonists 
  The first mGlu 5 receptor antagonists were identified 
from agonists having either a glutamate or a phenylglycine 
moiety (Fig. 7). These antagonists bind competitively at the 
glutamate-binding site. These early competitive antagonists 
lacked subtype selectivity. For example, phenyglycine 
derivative  22 showed weak antagonist activity for human 
mGlu5 receptor, as well as antagonist activity for the mGlu1 
receptor [121]. 
  In contrast, the most widely known pharmacological tool 
for showing the therapeutic potential of mGlu5 receptor 
antagonists is MPEP. Both MPEP and the structurally related 
MTEP are highly selective antagonists for the mGlu1 
receptor [158-160]. These compounds are structurally 
distinct from glutamate and bind to an allosteric site in the 
transmembrane domain. After identifying MPEP and MTEP, 
many derivatives were disclosed in patents and in the 
literature. Several substitutions were introduced into the 3-
position of the phenyl ring of MPEP and the 5-position of 
the pyridine ring of MTEP. 
 Compound  23, a derivative with a methoxy group in the 
3-position of the benzene ring of MPEP, shows a similar 
potency for the mGlu5 receptor as MTEP. The methoxy 
group of 23 can be easily radiolabeled by a reaction of the 
phenolic intermediate with [
3H]-methyl iodide. This 
radioligand with high specific activity and radiochemical 
purity is useful for labeling the mGlu5 receptor [161]. 
Introduction of a methoxymethyl group into the 5-pyridyl 
position of MTEP gives 24 with a similar potency to MTEP 
[162]. A radioactive compound of 24 has also been 
synthesized and used for in vitro binding assays using either 
rat brain tissues or cells that express recombinant human 
mGlu5 receptors [163].  
  Additional modifications of the pyridine ring of MTEP 
were investigated. Introduction of pyridine at the 5-pyridyl 
position of MTEP and transformation of the isoquinoline 
ring from the pyridine ring of MTEP gave 25 and 26, 
respectively. These compounds show high in vitro potencies 
(25, IC50 = 22 nM, Ki = 28 nM; 26, IC50 = 20 nM) [164, 
165]. Further explorations of mGlu5 receptor agonists by 
high-through-put-screening and optimization led to a novel 
series of pyridinyl-alkyne derivatives that were structurally 
related to MPEP (25: IC50 = 15 nM) [166]. Recently, a novel 
phenyl-alkyne derivative was disclosed as an mGlu5 
receptor antagonist (28: IC50 = 290 nM) [167]. 
 Aryl  benzoxazole  29 was identified by high-through-put-
screening as a potent mGlu5 receptor antagonist [168]. 
Compound 30 containing an oxazole ring substituted with an 
aryl group was disclosed in a patent [169]. However, 29 was 
not suitable for in vivo studies due to its poor solubility and 
 
 
 
 
 
 
 
 
Fig. (4). Competitive mGlu1 receptor antagonists. 
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poor pharmacokinetic profile (oral bioavailability F = 0.7 %) 
[168]. Compound 29 was modified based on SAR studies of 
the common structural features of 29, oxazole derivative 30, 
MPEP and MTEP to reveal a series of azole derivatives 
containing a pyridine and 1 or 2 phenyl rings, such as 31 
[170]. 
  Recently, some new classes of mGlu 5 receptor 
antagonists, dipyridyl amine 32, thiopyrimide 33, and 
arylmethoxypyrimide derivative 34, were identified by high-
through-put screening (32; IC50 = 12 nM, 33; IC50 = 80 Nm 
34; Ki = 1 nM). Compounds 32 and 34 have low to moderate 
oral bioavailabilities (32; F = 38 %, 34; F = 4.7 %).  
4.6. mGlu7 Receptor Ligands 
  To date, mGlu7 ligands are poorly represented in the 
literature. Only a mGlu7 receptor-selective agonist has been 
described, AMN082 (Fig. 8) [171, 172]. This compound was 
identified using high-throughput screening as the first full 
allosteric agonist for the mGlu7 receptor. This compound is 
structurally unrelated to any known mGlu receptor ligand. 
AMN082 has a unique mechanism of action by fully 
activating mGlu7 receptor through an allosteric site far 
removed from the glutamate-binding pocket [98].  
  There are only a limited number of selective mGlu7 
receptor antagonists. MDIP was identified by high- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Non-competitive mGlu1 receptor antagonists. 
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Fig. (6). mGlu5 receptor agonists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Antagonists of mGlu 5 receptor. 
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Fig. (8). mGlu7 receptor ligands. 
 
Table 2.  Possible Therapeutic Indications for Agents Acting on mGlu Receptors 
 
Group   Subtype   Possible Therapeutic Indications 
agonists/PAMs cognitive  disorders  mGlu1  
antagonists  anxiety, schizophrenia, pain 
agonists/PAMs  schizophrenia, cognitive disorders 
Group I
mGlu5
antagonists 
depression/anxiety, pain, drug addiction, 
gastroesphageal reflux disease, 
Parkinson's disease, migrain 
agonists/PAMs schizophrenia,  anxiety  mGlu2
antagonists  depression/anxiety, cognitive disorders 
agonists/PAMs schizophrenia 
Group II
mGlu3
antagonists ? 
agonists/PAMs  Parkinson's disease, anxiety (?)  mGlu4
antagonists ? 
agonists/PAMs depression/anxiety  (?)  mGlu7
antagonists depression/anxiety  (?) 
agonists/PAMs ?   mGlu6
antagonists ? 
agonists/PAMs depression/anxiety  (?) 
Group III
mGlu8
antagonists ? 
 
throughput screening, and MMPIP was synthesized by 
chemical modification of the phenyl group in the isoxazole 
ring system to a pyridyl group. In a cAMP assay, MDIP and 
MMPIP had IC50 values of 99 nM and 220 nM, respectively. 
The inhibitory modes of these compounds are non-
competitive and allosteric, and MMPIP appears to have an 
inverse agonist activity [173]. 
CONCLUSIONS AND FUTURE DIRECTIONS 
  Accumulating evidence indicates that mGlu receptors are 
significantly involved in psychiatric disorders and may serve 
as intriguing targets for drug discovery for the treatment of 
psychiatric disorders (Table 2). Among the mGlu receptors, 
mGlu2/3 receptor agonists have been proven to be effective 
for the treatment of not only schizophrenia, but also certain 
anxiety disorders in clinical settings. LY354740 was shown 
to exert anxiolytic effects in a fear-potentiated startle model 
in human volunteers [7], and LY354740 or LY544344, a 
prodrug of LY354740, showed efficacy in human anxiety 
models (panic provocation induced by the intravenous 
injection of cholecystokinin tetrapeptide or CO2 challenge) 
[8, 9]. Therefore, together with the recent remarkable find-
ings that LY2140023, a prodrug of the mGlu2/3 receptor 
agonist LY404039, provided improvements for both positive 
and negative symptoms of schizophrenia, mGlu2/3 receptor 
stimulation has paved the way for developing novel 
approaches beyond monoamine therapy for the treatment of 
psychiatric disorders, such as schizophrenia and anxiety. 
  Preclinical evidence is accumulating on the efficacy of 
mGlu2/3 receptor antagonists (depression), mGlu5 receptor 
agonists/potentiators (schizophrenia) and mGlu5 receptor 
antagonists (depression) in several animal models. Although 
a large number of patents for these targets have been 
published, there are few compounds that have entered 
clinical trials. Human proof-of-concept studies with 
compounds acting on the above mGlu receptors are 
necessary in order to address the utility of these mGlu 
receptors for treating psychiatric disorders. 
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